EGFR and non-small cell lung carcinoma: The treatment of non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations radically changed after the introduction of EGFR tyrosine kinase inhibitors (TKIs) to clinical practice, both in a metastatic setting [1,2] and in earlier stages of disease [3,4].